🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchSurvodutide (GCG/GLP-1) — MASH and obesity trial results Page 3

Survodutide (GCG/GLP-1) — MASH and obesity trial results

MASHdoc_SA Sat, Jun 6, 2026 at 8:40 PM 16 replies 467 viewsPage 3 of 4
EndoResFellow
Member
456
2,345
Sep 2024
Baltimore, MD
Jun 7, 2026 at 6:10 PM#11
hans_munich said:
The liver data is among the strongest non-weight findings in the class.

Thank you — that is the clearest version of this I have read, and I have read a lot of them.

33 8robert_kc, dan_philly, MeganSA_TX and 30 others
Reply Quote Save Share Report
Dr.LipidDallas
VIP Member
2,678
14,567
Dec 2023
Dallas, TX
Jun 7, 2026 at 9:01 PM#12

Adding the clinical framing, because it changes how the question reads. It helps to ask what evidence would change your mind before you look at any. If nothing would, the discussion is not about evidence, and it is better to say so early than to spend nine posts discovering it.

Worth separating that from liver and MASH, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

Last edited: Jun 7, 2026 at 11:01 PM
32 7wei_SG, cory_ATX, lori_vegas and 29 others
Reply Quote Save Share Report
PharmacoVig_BOS
Senior Member
1,567
8,901
Feb 2024
Boston, MA
Jun 7, 2026 at 11:52 PM#13
Dr.KarenChen said:
Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the…

I read this differently. The confidence in this thread is running ahead of the evidence, and I would rather the uncertainty were stated than smoothed over because it is unsatisfying.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

31 6DataDave, Dr.GutHealth, amsterdam_pete and 28 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
dan_philly
Member
456
2,123
Jul 2024
Philadelphia, PA
Jun 8, 2026 at 2:44 AM#14

Adding the numbers, since they settle part of this. If you are comparing against somebody else’s result, check that you are comparing the same measurement taken the same way. Most of the apparent contradictions in these threads dissolve at that step.

30 5Dr.CardioMD, EndoResFellow, PharmacoVig_BOS and 27 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Jun 8, 2026 at 5:35 AM#15

Moderator note: a couple of off-topic posts removed. Tagging this one for the weekly digest.

Last edited: Jun 8, 2026 at 9:35 AM
29 4PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 26 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register